GTx, Inc. To Present At The Lazard Life Sciences Conference

MEMPHIS, Tenn., Nov. 23 /PRNewswire-FirstCall/ -- GTx, Inc. , a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for serious men's health conditions, today announced that the Company is scheduled to present at the Lazard Life Sciences Conference on Tuesday, November 30, 2004. Mitchell Steiner, M.D., Vice Chairman and CEO of GTx, Inc. will give a corporate update at 11:00 a.m. Eastern Time, at the Mandarin Oriental in New York.

The live audio broadcast and the subsequent archived recording of the presentation will be available on the Company's website at http://www.gtxinc.com/ until December 31, 2004.

About GTx

GTx is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for serious men's health conditions. GTx's drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens. GTx currently has two product candidates that are in human clinical trials. The company is developing ACAPODENE(TM), its most advanced product candidate, through clinical trials for two separate indications: (1) a planned pivotal Phase III clinical trial for the reduction in the incidence of prostate cancer in high risk men and (2) a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer. GTx is developing its second product candidate, andarine, and other specified backup compounds, with its partner, Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson. It is currently anticipated that andarine will be entering a Phase II clinical trial in 2005. GTx is developing another one of its SARMs, ostarine, for andropause which will be entering a Phase I clinical trial in 2005. GTx has a deep pipeline generated from its own discovery program which includes specific product candidates prostarine, a SARM for benign prostatic hyperplasia or BPH, and andromustine, an anticancer drug, for hormone refractory prostate cancer.

Forward-Looking Statement

This press release contains forward-looking statements, including, without limitation, statements related to GTx's current and anticipated clinical trials and research and development programs. These forward-looking statements are based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties. GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that neither GTx nor its partner will be able to commercialize its product candidates if preclinical studies do not produce successful results or clinical trials do not demonstrate safety and efficacy in humans; if third parties do not manufacture the Company's product candidates in sufficient quantities and at an acceptable cost, clinical development and commercialization of its product candidates would be delayed; use of third- party manufacturers may increase the risk that the Company will not have adequate supplies of its product candidates; if third parties on whom the Company relies do not perform as contractually required or expected, the Company may not be able to obtain regulatory approval for or commercialize its product candidates; the Company is dependent upon collaborative arrangements to complete the development and commercialization of some of its product candidates, and these collaborative arrangements may place the development of its product candidates outside its control, may require it to relinquish important rights or may otherwise be on terms unfavorable to the Company; and if the Company is not able to obtain required regulatory approvals, the Company will not be able to commercialize its product candidates. The annual report filed on Form 10-K with the U.S. Securities and Exchange Commission on March 26, 2004 contains under the heading "Additional Factors That Might Affect Future Results" a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact: GTx, Inc. Burns McClellan, Inc. Carney Duntsch Jonathan M. Nugent (investors) Investor and Media Relations Kathy L. Jones-Nugent, Ph.D. (media) 901-523-9700 212-213-0006 cduntsch@gtxinc.com

GTx, Inc.

CONTACT: Carney Duntsch, Investor and Media Relations of GTx, Inc.,+1-901-523-9700, or cduntsch@gtxinc.com; or Jonathan M. Nugent (investors), orKathy L. Jones-Nugent, Ph.D. (media), both of Burns McClellan, Inc.,+1-212-213-0006, for GTx, Inc.

Back to news